| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
chromosome 20 open reading frame 181 | 0.479 | 0.885 |
|
group | 0.070 | None | 1.000 | 7 | 0 | 1994 | 2019 | |||||||||
|
Pulmonary disease, chronic obstructive, severe early-onset | 0.456 | 0.885 |
|
group | 0.040 | None | 1.000 | 4 | 0 | 2019 | 2019 | |||||||||
|
adeno-associated virus integration site 1 | 0.595 | 0.731 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2005 | 2007 | |||||||||
|
microRNA 122 | 0.468 | 0.808 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2014 | 2016 | |||||||||
|
triiodothyronine receptor auxiliary protein | 0.579 | 0.731 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2018 | 2018 | |||||||||
|
long intergenic non-protein coding RNA 1672 | 0.462 | 0.846 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 1989 | 1989 | |||||||||
|
interferon lambda 4 (gene/pseudogene) | 0.670 | 0.577 |
|
group | 0.010 | None | 1.000 | 1 | 1 | 2017 | 2017 | |||||||||
|
RNA, 7SL, cytoplasmic 263, pseudogene | 0.496 | 0.808 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
MAS related GPR family member X3 | 0.529 | 0.923 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
MAS related GPR family member X4 | 0.531 | 0.923 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
Prader Willi/Angelman region RNA 1 | 0.490 | 0.769 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2005 | 2005 | |||||||||
|
MAS related GPR family member X1 | 0.531 | 0.923 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
ceruloplasmin pseudogene | 0.631 | 0.731 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
interferon alpha 2 | 0.442 | 0.885 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2002 | 2002 | |||||||||
|
Prader Willi/Angelman region RNA 4 | 0.573 | 0.769 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2002 | 2002 | |||||||||
|
microRNA 106a | 0.524 | 0.846 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2016 | 2016 | |||||||||
|
microRNA 197 | 0.565 | 0.615 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2016 | 2016 | |||||||||
|
POTE ankyrin domain family member K, pseudogene | 0.542 | 0.769 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2018 | 2018 | |||||||||
|
vomeronasal 1 receptor 17 pseudogene | 0.529 | 0.923 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
G protein-coupled receptor 166 pseudogene | 0.531 | 0.923 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
platelet and endothelial cell adhesion molecule 1 | 0.426 | 0.846 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | |||||||||
|
IgA nephropathy | 0.524 | 0.808 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
CXADR pseudogene 1 | 0.463 | 0.846 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | |||||||||
|
Myeloproliferative syndrome, transient (transient abnormal | 0.528 | 0.731 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2008 | 2008 | |||||||||
|
lipoprotein(a) | 0.444 | 0.769 | 6.6E-89 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 1995 | 1995 |